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Abstract
Introduction: Endothelial cell injury is an important component of acute lung injury. Platelet-endothelial cell
adhesion molecule-1 (PECAM1) is a transmembrane protein that connects endothelial cells to one another and can
be detected as a soluble, truncated protein (sPECAM1) in serum. We hypothesized that injurious mechanical
ventilation (MV) leads to shedding of PECAM1 from lung endothelial cells resulting in increasing sPECAM1 levels in
the systemic circulation.
Methods: We studied 36 Sprague–Dawley rats in two prospective, randomized, controlled studies (healthy and
septic) using established animal models of ventilator-induced lung injury. Animals (n= 6 in each group) were
randomized to spontaneous breathing or two MV strategies: low tidal volume (VT) (6 ml/kg) and high-VT (20 ml/kg)
on 2 cmH2O of positive end-expiratory pressure (PEEP). In low-VT septic animals, 10 cmH2O of PEEP was applied. We
performed pulmonary histological and physiological evaluation and measured lung PECAM1 protein content and
serum sPECAM1 levels after four hours ventilation period.
Results: High-VT MV caused severe lung injury in healthy and septic animals, and decreased lung PECAM1 protein
content (P < 0.001). Animals on high-VT had a four- to six-fold increase of mean sPECAM1 serum levels than the
unventilated counterpart (35.4 ± 10.4 versus 5.6± 1.7 ng/ml in healthy rats; 156.8± 47.6 versus 35.6± 12.6 ng/ml in
septic rats) (P< 0.0001). Low-VT MV prevented these changes. Levels of sPECAM1 in healthy animals on high-VT MV
paralleled the sPECAM1 levels of non-ventilated septic animals.
Conclusions: Our findings suggest that circulating sPECAM1 may represent a promising biomarker for the
detection and monitoring of ventilator-induced lung injury.
Introduction
Mechanical ventilation (MV) is the most important sup-
portive tool in the care of critically ill patients with acute
respiratory failure. However, although necessary to pre-
serve life, MV can itself aggravate or cause lung damage
through a variety of mechanisms collectively referred to as
ventilator-induced lung injury (VILI) [1]. These mecha-
nisms include exposure to high inflation pressures, alveo-
lar overdistension, and repetitive opening and closing of
alveoli. In addition to direct structural damage to the
lungs, these mechanical forces may lead to up-regulated
cytokine release and a systemic inflammatory response,
propagating injury to non-pulmonary organs, which may
result in multiple organ failure, and ultimately affect out-
come [2-4]. Our improved understanding of acute lung
injury and VILI in patients with the acute respiratory dis-
tress syndrome (ARDS) has been important in designing
lung-protective MV strategies aimed at attenuating VILI
and improving outcomes. The only strategy that has dem-
onstrated improved survival in ARDS patients is the use of
low tidal volume (VT) MV with adequate positive end-
expiratory pressure (PEEP) and limited transpulmonary
distending pressure [5]. This strategy aims to minimize
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peated opening and closing of lung units.
Considerable effort has been made to enhance our
mechanistic understanding of VILI. Endothelial cell in-
jury is an important component of ARDS and VILI, and
the most fundamental early physiologic characteristic is
an increase in protein permeability across the endothe-
lial barrier of the lung. The damage observed in ARDS
and VILI reflects the primary injurious stimuli and the
secondary complex interactions of inflammatory media-
tors on alveolar epithelial and capillary endothelial cells
[1,4]. Mechanical forces within the alveolus can cause
endothelial disruption and hemorrhagic injury, even in
the absence of pre-existing inflammation [6], and lead to
activation of downstream messenger systems [7-11].
Platelet-endothelial cell adhesion molecule-1 (PECAM1)
is a 130 kDa transmembrane protein member of the im-
munoglobulin superfamily of cell adhesion molecules
that is constitutively localized at cell-cell junctions that
connect endothelial cells to one another [12]. PECAM1
can be cleaved from endothelial cells, resulting in a se-
creted, shed protein (sPECAM1) [13,14]. Since pulmon-
ary inflammation is a central component of VILI, and
PECAM1 has been shown to mediate endothelial cell
permeability [12], we hypothesized that PECAM1 can be
cleaved and shed from the surface of endothelial cells
and detected in the systemic circulation after a short
term of injurious MV in an experimental, clinically rele-
vant animal model of VILI using healthy and septic
animals.
Materials and methods
All experimental protocols were approved by the Animal
Use and Care Committees at Hospital Universitario Dr.
Negrin (Las Palmas, Spain) and Hospital Universitario
NS de Candelaria (Tenerife, Spain) in accordance with
the European Commission Directive 2010/63/EU for
animal experimentation.
Animal preparation and experimental protocol
We studied 36 male healthy and septic Sprague–Dawley
rats weighing 300 to 350 g included in two prospective,
randomized, controlled studies that survived after a four-
hour ventilation period using two well-established models
of VILI. Briefly, in the first animal model of VILI, anes-
thetized (intraperitoneal injection of 80 mg/kg ketamine
hydrochloride and 8 mg/kg xylazine) healthy animals were
randomized into three groups (n=6 in each group): (1)
spontaneous breathing; (2) MV with low-VT (6 ml/kg) plus
2c m H 2O of PEEP; and (3) MV high-VT (20 ml/kg) plus 2
cmH2O of PEEP. In the animal model of sepsis-induced
lung injury, sepsis was induced by cecal ligation and punc-
ture (CLP). A detailed description of this experimental
model is provided elsewhere [10]. Eighteen surviving septic
animals at 18 hours after CLP were anesthetized and
randomly assigned to three groups (n=6 in each group):
(4) spontaneous breathing; (5) MV with low-VT plus 10
cmH2O of PEEP; and (6) MV with high-VT plus 2 cmH2O
of PEEP. In healthy and septic animals assigned to MV, we
performed a tracheotomy using a 14-G Teflon catheter.
Thereafter, animals were paralyzed with 1 mg/kg pancuro-
nium bromide and connected to a time-cycled, volume-
limited rodent ventilator (Ugo Basile, Varese, Italy). During
MV, healthy animals were on fraction of inspired oxygen
(FiO2) = 0.4 and septic animals on FiO2=0.6. Respiratory
rate was set to maintain constant minute ventilation in all
ventilated groups.
The experimental settings were maintained for four
hours, while animals were anesthetized and paralyzed by
bolus administration of intraperitoneal ketamine/xylazine
and pancuronium bromide every 45 minutes. Animals
were monitored non-invasively to minimize the possibility
of triggering an inflammatory response, after establishing a
protocol which provided hemodynamic stability and com-
parable blood gases in invasively monitored animals during
the four-hour experimental period. Peak airway pressures
were continuously monitored. Oxygen saturation (SpO2)
was continuously measured using a pulse oxymeter applied
to the rat’s tongue. SpO2 remained ≥90% in all animals
during animal instrumentation. Animals were maintained
supine on a restraining board inclined 20° from the
horizontal.
Gas exchange and histological examination
At the end of the four-hour observation and ventilation
period, a midline thoracotomy/laparotomy was performed
and, after sampling arterial blood for gases and serum ana-
lysis by abdominal aorta puncture, animals were sacrificed
by supplemental pentobarbital (10 mg/kg) and exsanguin-
ation after sectioning the abdominal vessels. The heart and
lungs were removed ‘en bloc’. The lungs were isolated from
the heart, the trachea was cannulated, and the right lung
was fixed by intratracheal instillation of 3 ml 10% formalin.
After fixation, lungs were floated in 10% formalin for a
week. Then, lungs were sampled in multiple areas and
sliced from apex to base and embedded in paraffin, then
cut (3 μm thickness sections), stained with hematoxylin-
eosin and examined by two pathologists (FV, MLH) who
were blinded to group identity. Slides were viewed using
a Nikon Optiphot light microscope (Tokyo, Japan) and
photographed with a Nikon Digital DS-5 M camera
(Tokyo, Japan) at×200 magnification. Three random sec-
tions of the right lung from each animal were examined
with particular reference to alveolar and interstitial damage
defined as cellular inflammatory infiltrates, pulmonary
edema, disorganization of lung parenchyma, alveolar rup-
ture and hemorrhage. By scoring from 0 to 4 (none, mild,
moderate, severe, very severe) for each parameter, a total
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individual scores in every animal and averaging the total
values in each animal group.
Protein extraction and PECAM1 immunoblotting
Left lungs from each experimental condition were ex-
cised, washed with saline, frozen in liquid nitrogen and
stored at -80°C for subsequent protein extraction and
blotting. Lungs were sampled in multiple areas, homoge-
nized, and proteins were extracted by centrifugation
(14,000 rpm) for five minutes at 4°C. Protein content in
the supernatant of the extract was measured with Bio-Rad
DC Protein Assay (Hercules, CA, USA). Western blotting
was performed using a rabbit polyclonal anti-PECAM1
antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). β-actin antibody (Cell Signaling Technology,
Danvers, MA, USA) was used as loading control after
stripping the membrane using Restore Western Blot
Stripping Buffer. In all cases, bands were detected by
chemiluminescence and measured by Scion Image
software package (Scion Corp., Frederick, MD, USA).
sPECAM1 serum levels
At the end of every experiment, blood collected in each
animal was centrifuged for 15 minutes at 3,000 rpm. Sera
were divided into aliquot portions and frozen at -80°C.
sPECAM1 concentrations in serum were measured by
enzyme-linked immunosorbent assay (ELISA) in dilutions
that allowed interpolation from a simultaneously run
standard curve. Levels of sPECAM1 were measured with a
commercially available ELISA kit specific for rats (Cusabio,
Wuhan Huamei Biotech, Wuhan, Hubei, China) following
specifications of the manufacturer. Samples were analyzed
using a fully automated ELISA analyzer (Triturus, Grifols,
Spain). This assay has high sensitivity and excellent specifi-
city for detection of rat sPECAM1 and eliminates interfer-
ence by soluble receptors, binding proteins, and other
factors present in biological samples. sPECAM1 concen-
trations are expressed as ng/ml. The detection range is 3.1
to 200 ng/ml.
Data analysis
Data are expressed as mean ±standard deviation (SD).
Comparisons involving all experimental groups were
performed with one-way analysis of variance. We used a
Bonferroni correction for multiple comparisons. Values
derived from Western blot densitometry were expressed
as group mean, normalized to β-actin and expressed as
fold-changes of ventilated lungs versus control (non-
ventilated) lungs, and tested with the same statistical
analyses. Data analysis was performed using SPSS (SPSS
Inc, Chicago, IL, USA). A two-sided P-value <0.05 was
considered significant.
Results
Respiratory parameters and pathological evaluation
In healthy ventilated animals, mean peak inspiratory
pressures were 14±1 and 24± 2 cmH2O for the low-VT
and high-VT groups, respectively (P <0.0001). In septic
ventilated animals, mean peak inspiratory pressures were
20± 1 and 28±2 cmH2O for the low-VT and high-VT
groups, respectively (P <0.0001). Mean partial pressure
of arterial CO2 (PaCO2) did not differ among subgroups
in each category (42±2 versus 40 ±2 mmHg for low-VT
versus high-VT healthy groups; 42± 2 versus 39.5 ±
3 mmHg for low-VT versus high-VT septic groups).
Healthy animals ventilated with high-VT and septic an-
imals on spontaneous breathing or high-VT MV had
histological and gas exchange evidence of lung injury
(Figure 1A, B). Mean ratio of arterial partial pressure of
oxygen to fraction of inspired oxygen (PaO2/FiO2) in the
low-VT control group was over 400 mmHg; in contrast,
mean PaO2/FiO2 in healthy high-VT animals (250 ±
20 mmHg), and in septic animals ventilated with low-VT
plus PEEP (265 ±38 mmHg) or with high-VT (211 ±
28 mmHg) met oxygenation criteria for acute lung injury
[5] (Figure 1B).
After four hours of high-VT MV, the lungs showed acute
inflammatory infiltrates and perivascular edema. Septic
animals ventilated with high-VT had the highest histo-
logical injury scores (12.2±2.3) whereas healthy animals
ventilated with low-VT had the lowest score (1.1±0.3)
(Figure 1C). Septic animals ventilated with low-VT plus
PEEP had a lower histological score than septic, spon-
taneous breathing animals (3.3 ±0.5 versus 5.4± 0.7)
(P =0.001). These results confirmed that high-VT MV
and sepsis alone caused acute lung injury, and high-VT
MV further enhanced sepsis-induced lung injury.
Lung PECAM1 protein content
MV and sepsis decreased PECAM1 protein content in the
lungs depending on the ventilatory strategy (Figure 2).
Healthy animals from the non-ventilated and low-VT
groups had similar levels of PECAM1. However, high-VT
MV was accompanied by a marked reduction of PECAM1
lung levels (P <0.001). Overall, these data suggest an early
reduction of cell-cell adhesions of endothelial cells in
healthy and septic lungs after four hours of injurious MV.
sPECAM1 serum levels
Animals on high-VT MV had a four- to six-fold increase
of mean sPECAM1 serum levels than their unventilated
counterparts (35.4±10.4 versus 5.6±1.7 ng/ml in healthy
rats; 156.8±47.6 versus 35.6±12.6 ng/ml in septic rats)
(P <0.0001 for both comparisons) (Figure 3). However,
low-VT MV prevented such drastic changes when com-
pared to the unventilated counterpart. Increases in the
levels of sPECAM1 in healthy animals on high-VT MV
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mals on spontaneous breathing and on low-VT MV.
Discussion
Our study suggests a new order of complexity in regulating
the bridge between MV, sepsis and ARDS. The mechanisms
of VILI have been extensively reviewed in the past 20 years
[2,16,17]. Repeated overexpansion of the lung increases
microvascular permeability and leads to edema formation
without actual rupture of the lung. Electron microscopy
has demonstrated ‘capillary stress fractures’ when micro-
vascular pressures are markedly elevated [18]. It is this
‘stress failure’ of the alveolar capillary membrane that is re-
sponsible for the increased microvascular permeability
edema seen with lung overinflation. Because the pulmonary
endothelial barrier is damaged during sepsis, ARDS and
VILI, lung cytokines released into the circulation can initi-
ate or propagate a systemic inflammatory response and play
an active role in the development of multiple system organ
dysfunctions [19]. In our study, the application of low-VT
plus PEEP dramatically reduced lung injury in septic ani-
mals, a finding that has been previously reported by our
group and by several other investigators [2,15,20,21].
The present study is the first to demonstrate that: (1)
PECAM1 expression is modulated in the lungs in re-
sponse to MV in the presence or absence of sepsis; (2)
the expression of PECAM1 is dependent on the MV re-
gime applied; and (3) the circulating levels of sPECAM1
are rapidly and markedly increased during injurious MV.
PECAM1 is expressed on the surface of hematopoietic
and immune cells and is highly enriched at endothelial
cell-junctions [13,14,22]. Since its cloning in 1990 [23],
there has been enormous progress in understanding the
biology of PECAM1 and there is now clear evidence for
its involvement in regulating leukocyte migration and in-
flammatory and vascular responses in numerous disease
processes, including sepsis [12]. There is growing evi-
dence that PECAM1 not only contributes to the main-
tenance of vascular integrity in resting cells but also to
its restoration following barrier disruption [24] because
Figure 1 Histological and gas-exchange findings. (A) Representative histological features of different ventilatory strategies in healthy and
septic lungs. Animals ventilated with high tidal volume showed abundant pulmonary infiltrates and perivascular edema (hematoxylin-eosin,
×200). (B) PaO2/FiO2 ratios at the end of a four-hour ventilation period. ***P<0.001 (HVT versus LVT); *P<0.05 (SHVT versus SLVT). (C) Histological
lung injury score. ***P<0.001 (HVT versus LVT; SHVT versus S and SLVT; SLVT versus S). C: healthy control, spontaneous breathing lung; LVT:
healthy, ventilated with low tidal volume; HVT: healthy lung ventilated with high tidal volume; S: septic, spontaneous breathing rats; SLVT: septic
lung ventilated with low tidal volume; SHVT: septic lung ventilated with high tidal volume. PaO2/FiO2, ratio of arterial partial pressure of oxygen
to fraction of inspired oxygen.
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http://ccforum.com/content/18/2/R41Figure 2 Western blot and densitometry analysis of PECAM-1 protein in the lungs. Experimental groups: healthy, spontaneous breathing
control rats (C); healthy, ventilated with low tidal volume (LVT); healthy, ventilated with high tidal volume (HVT); septic, spontaneous breathing
animals (S); septic, ventilated with low tidal volume (SLVT); septic, ventilated with high tidal volume (SHVT). ***P <0.001 (HVT versus C and LVT;
SHVT versus S and SLVT); ¶ P <0.001 for S versus C. PECAM1, platelet endothelial cell adhesion molecule-1.
Figure 3 Serum levels of soluble platelet endothelial cell adhesion molecule 1 (sPECAM1) in healthy and septic animals. Experimental
groups: healthy, spontaneous breathing control rats (C); healthy, ventilated with low tidal volume (LVT); healthy, ventilated with high tidal volume
(HVT); septic, spontaneous breathing animals (S); septic, ventilated with low tidal volume (SLVT); septic, ventilated with high tidal volume (SHVT).
***P <0.0001 (HVT versus C and LVT; SHVT versus S and SLVT).
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lishment of the vascular permeability barrier after hista-
mine challenge [25] or in response to physical injury [26].
It has been reported that lung samples of patients who
died from ARDS had a heterogeneous expression of
PECAM1 in blood vessels [27]. Other studies have shown
down-regulation of PECAM1 in neutrophils from patients
with major trauma [28] and in the lungs of children who
died from bronchopulmonary dysplasia after being mech-
anically ventilated [29]. Our data strongly suggest that the
loss of PECAM1 in the lungs, which occurred in response
to lung overstretch, compromises the permeability barrier
and leads to edema formation and leukocyte infiltration
(as seen by histological examination) and severe hypox-
emia (as shown by a marked decrease of the PaO2/FiO2
ratio). Of note, lung PECAM1 content in septic animals
ventilated with low-VT plus 10 cmH2Oo fP E E P ,as o -
called protective MV strategy, remained higher, at levels
very similar to non-septic animals. Also, the application of
a protective MV strategy in animals with sepsis-induced
lung injury prevented the increase of circulating serum
levels of sPECAM1, which was associated with a lower
histological lung injury score and a higher PECAM1 pro-
tein content in the lungs.
Little is known about the biochemical events involved in
PECAM1 synthesis and processing in endothelial cells.
Synthesis of PECAM1 is tightly regulated, as it is not
found outside the vasculature. The specific mechanism by
which PECAM1 functions to maintain or repair vascular
barrier integrity is still poorly understood [24]. Levels of
circulating PECAM1 particles shed from damaged endo-
thelial cells have been reported as a marker of endothelial
injury and to be present in various inflammatory diseases,
including sepsis [14,30-34]. Current evidence suggests that
activated inflammatory cells undergo an active shedding
of the extracellular domain of the PECAM1 molecule
which could contribute to the loss of cell-cell adhesion
[13] and to the rise in circulating sPECAM1 during in-
flammatory diseases [14]. Our translational model of
sepsis-induced lung injury is considered as the gold stand-
ard in sepsis and ARDS research that closely mimics the
pathophysysiology of human sepsis [35] and ARDS [10].
In our study, the detection of elevated sPECAM1 serum
levels in animals ventilated with high-VTsupports the con-
cept of a primary endothelial cell involvement in the
pathogenesis of increased vascular permeability seen in
VILI and sepsis-induced ARDS. In this context, serial
measurements of sPECAM1 levels could be used to assess
prognosis or to monitor the benefits of endothelium-
protective therapy. sPECAM1 is present in normal human
plasma at levels of 10 to 25 ng/ml that are not associated
with cellular debris or platelet microparticles [36]. Al-
though the role of sPECAM1 serum levels in vivo remains
to be determined, the membrane-anchored protein is
required for transendothelial migration of leukocytes
[12,37]. Thus, under normal conditions, the presence of
low levels of sPECAM1 is indicative of normal functioning
of PECAM1 as counteracting the tendency of leukocytes
to leave the vasculature, whereas higher circulating levels
of sPECAM1, as occurs during inflammatory conditions
such as sepsis, ARDS and VILI, could serve as diagnostic
and prognostic biomarkers of endothelial dysfunction.
Measuring circulating sPECAM1 levels could help to
identify and monitor the management of septic and ARDS
patients with different degrees of severity. Our findings on
assessment of sPECAM1 levels under distinct modes of
MV meet most of the criteria proposed by Shehabi and
Seppelt [38] when seeking an ideal biomarker: ‘aS M A R T
biomarker is Sensitive, Measurable (with a high degree of
precision), Available (Affordable and safely Attainable),
and Responsive (and Reproducible) in a Timely fashion to
expedite clinical decision making’. A low sPECAM1 level
is associated with normal or improved endothelial function
and may be a marker of successful response to conven-
tional therapy. By contrast, a high sPECAM1 level may be
considered a marker of failure to respond to therapy and
may require additional treatments to improve outcome.
We used a VT of 20 ml/kg, a value that although higher
than those used clinically, produces stretch that is likely
comparable to that experienced by some patients with
acute lung injury or ARDS in nondependent areas of the
lung, even when relatively small VTare used. In experimen-
tal models, VILI develops when a lung strain (estimated as
the ratio between lung volume change and resting volume)
greater than two is achieved, corresponding to VT of ap-
proximately 20 ml/kg in healthy animals [39,40]. In our
preliminary experiments, we found that 20 ml/kg was the
minimal level of overdistension that caused an easily identi-
fiable injury during a short period of MV. Supraphysiologic
VT has been used since the classical paper by Web and
Tierney [20] for investigating lung injury in in vivo venti-
lated small experimental animals [41]. This approach re-
flects the compromise between limiting the ventilation
p e r i o dt oaf e wh o u r s( i no r d e rt ol i m i tt h er o l eo fc o n -
founding factors such as anesthesia, fluid status, infection,
nutrition and so on) and the attempt to produce detectable
lung injury in a very short time. We used a level of 2
cmH2O of PEEP in animals with previously healthy lungs.
This level of PEEP in healthy lungs is sufficient to avoid
atelectasis during the four-hour MV period. There is no
documented need for using high levels of PEEP during a
short-term MV period in animals with healthy lungs. In a
previous study by our group [6], we demonstrated that the
use of 10 cmH2O to a constant large VT (20 ml/kg) exacer-
bated VILI in previously healthy animals. However, in
sepsis-induced lung injury animals, we used 10 cmH2Oo f
PEEP in the low-VT group since it is within the range of
PEEP levels used in the management of patients with
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because in previous pilot studies, some animals ventilated
with high-VTand breathing room air developed hypoxemia
at the end of the four-hour MV period. We used a FiO2 of
0.6 in animals with sepsis-induced lung injury because in
previous experiments using 40% oxygen in the CLP model,
some septic animals ventilated with high-VT developed
hypoxemia at the end of the four-hour MV period.
The present study has some limitations and strengths.
First, we have not explored whether the application of
protective MV after four hours of high-VT MV could de-
crease the elevated sPECAM1 levels in healthy and sep-
tic animals with VILI. This should be determined in
future experimental studies. Since PECAM1 is required
for restoring endothelial continuity, targeting PECAM1
integrity may open new therapeutic approaches for sep-
sis and ARDS. In a model of endotoxic shock, Maas
et al. [42] were able to transplant bone marrow cells ex-
pressing PECAM1 into PECAM1-deficient mice and
found that the animals became resistant to endotoxic
shock and maintained an intact vascular permeability
barrier after endotoxin administration. Second, although
both injurious MV and sepsis alone increased circulating
sPECAM1 serum levels, our data demonstrated that
sPECAM1 levels are more sensitive to MV than to the
underlying disease process. This should be confirmed in
future experimental and clinical studies. Third, pulmonary
vascular stress was not assessed in our study and it may
have contributed to the development of VILI [43-45].
However, based on our pilot data, the approaches used to
ventilate these animals did not markedly increase intravas-
cular stress.
Searching for biomarkers for sepsis, ARDS and VILI
has been an on-going journey in critical care research.
Many biomarkers proposed by experimental studies have
not been able to be applied in clinical practice. The lack
of convincing biomarkers further promotes investiga-
tions along this line. Usually, the experimental studies
have a very well defined mechanical ventilation setting,
inflammatory stimulus and other well-controlled condi-
tions, while clinically we are dealing with patients in
complicated situations. Therefore, it is critical to validate
biomarkers clinically. It is also important to compare
and combine different biomarkers in order to define and
differentiate different clinical conditions. It is our hope
that the present study will be able to stimulate more
interest and discussion of sPECAM1 and other bio-
markers for VILI.
Conclusions
We have demonstrated that high-VT MV decreased
PECAM1 protein content in the lung and increased
serum levels of sPECAM1. This effect was highest in an-
imals with sepsis-induced lung injury. By contrast,
protective MV restored PECAM1 protein levels and de-
creased serum levels of sPECAM1. These results imply
that PECAM1 is involved in the pathogenesis of VILI
and suggest that the protective mechanism of low-VT
plus PEEP is related to prevention or attenuation of pul-
monary endothelial injury. The measurement of sPE-
CAM1 may represent a novel, promising biomarker for
monitoring the development and progression of ARDS
and for the earliest identification of patients at risk of
developing VILI.
Key messages
 PECAM1 can be cleaved and shed from the surface
of endothelial cells and detected as a soluble,
truncated protein (sPECAM1) in the systemic
circulation after a short term of injurious
mechanical ventilation.
 The detection of elevated sPECAM1 serum levels
during high VT ventilation supports the concept of a
primary endothelial cell involvement in the
pathogenesis of increased vascular permeability seen
in VILI and in ARDS.
 Our study suggests that low levels of sPECAM1 are
indicative of normal functioning of PECAM1,
whereas higher circulating levels of sPECAM1, as
occurs during inflammatory conditions such as
sepsis, ARDS and VILI, could serve as diagnostic
and prognostic biomarkers of endothelial
dysfunction.
Abbreviations
ARDS: acute respiratory distress syndrome; CLP: cecal ligation and puncture;
ELISA: enzyme-linked immunosorbent assay; MV: mechanical ventilation;
PaO2/FiO2: ratio of arterial partial pressure of oxygen to fraction of inspired
oxygen; PECAM1: platelet endothelial cell adhesion molecule-1;
PEEP: positive end-expiratory pressure; sPECAM1: soluble platelet endothelial
cell adhesion molecule-1; SpO2: oxygen saturation by pulse oxymetry;
VILI: ventilator-induced lung injury; VT: tidal volume.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JV, MM, NC, CF, FV, JB and RMK conceived and designed the experiments; JV
obtained funding; JV, MM, NC, FV, MLH and JLMB performed the
experiments; JV, MM, NC, FV, MLH, JB and RMK coordinated data collection
and data quality; JV, MM, NC, FV, CF and ML analyzed the data; JV, MM, NC,
FV, MLH, CF, JB, JLMB, ML and RMK participated in the first draft of the
manuscript. All authors participated in the writing process of the manuscript
and read and approved the final manuscript.
Acknowledgements
Supported in part by grants (PI10/0393, CB06/06/1088) from Instituto de
Salud Carlos III, Madrid, Spain.
Author details
1CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid,
Spain.
2Multidisciplinary Organ Dysfunction Evaluation Research Network,
Research Unit, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria,
Spain.
3Keenan Research Center for Biomedical Science at the Li Ka Shing
Knowledge Institute, St. Michael’s Hospital, Toronto, Canada.
4Department of
Villar et al. Critical Care 2014, 18:R41 Page 7 of 9
http://ccforum.com/content/18/2/R41Clinical Biochemistry, Hospital Universitario NS de Candelaria, Tenerife, Spain.
5Department of Anatomy, Pathology & Histology, University of La Laguna,
Tenerife, Spain.
6Research Unit, Hospital Universitario N.S. de Candelaria,
Santa Cruz de Tenerife, Spain.
7Intensive Care Unit, Hospital Universitario Río
Hortega, Valladolid, Spain.
8Institute of Medical Science, Faculty of Medicine,
University of Toronto, Toronto, Canada.
9Respiratory and Critical Care
Research Group, Toronto General Research Institute, University Health
Network, Toronto, Canada.
10Department of Respiratory Care, Massachusetts
General Hospital, Boston, Massachusetts, USA.
11Department of
Anesthesiology, Harvard University, Boston, Massachusetts, USA.
Received: 15 October 2013 Accepted: 25 February 2014
Published: 3 March 2014
References
1. Pinhu L, Whiteheaqd T, Evans T, Griffiths M: Ventilator-associated lung
injury. Lancet 2003, 361:332–340.
2. Dreyfuss D, Saumon G: Ventilator-induced lung injury: lessons from
experimental studies. Am J Respir Crit Care Med 1998, 157:294–323.
3. Burns KE, Adhikari NK, Slutsky AS, Guyatt GH, Villar J, Zhang H, Zhou Q,
Cook DJ, Stewart TE, Meade MO: Pressure and volume limited ventilation
for the ventilatory management of patients with acute lung injury: a
systematic review and meta-analysis. PLoS One 2011, 6:e14623.
4. Villar J, Blanco J, Zhang H, Slutsky AS: Ventilator-induced lung injury and
sepsis: two sides of the same coin? Minerva Anestesiol 2011, 77:647–653.
5. Ventilation with lower tidal volumes as compared with traditional tidal
volumes for acute lung injury and the acute respiratory distress
syndrome. The Acute Respiratory Distress Syndrome Network.
N Engl J Med 2000, 342:1301–1308.
6. Villar J, Herrera-Abreu MT, Valladares F, Muros M, Pérez-Méndez L, Flores C,
Kacmarek RM: Experimental ventilator-induced lung injury. Exacerbation
by positive end-expiratory pressure. Anesthesiology 2009, 110:1341–1347.
7. Crosby LM, Waters CM: Epithelial repair mechanisms in the lung. Am J
Physiol Lung Cell Mol Physiol 2010, 298:L715–L731.
8. Nonas SA, Moreno-Vinasco L, Ma SF, Jacobson JR, Desai AA, Dudek SM,
Flores C, Hassoun PM, Sam L, Ye SQ, Moitra J, Barnard J, Grigoryev DN,
Lussier YA, Garcia JG: Use of consomic rats for genomic insights into
ventilator-associated lung injury. Am J Physiol Lung Cell Mol Physiol 2007,
293:L292–L302.
9. Hegeman MA, Hennus MP, Heijnen CJ, Specht PA, Lachmann B, Jansen NJ,
van Vught AJ, Cobelens PM: Ventilator-induced endothelial activation and
inflammation in the lung and distal organs. Crit Care 2009, 13:R182.
10. Villar J, Cabrera N, Casula M, Flores C, Valladares F, Muros M, Blanch L,
Slutsky AS, Kacmarek RM: Mechanical ventilation modulates Toll-like
receptor signaling pathway in a sepsis-induced lung injury model.
Intensive Care Med 2010, 36:1049–1057.
11. Villar J, Cabrera NE, Casula M, Flores C, Valladares F, Diaz-Flores L, Muros M,
Slutsky AS, Kacmarek RM: Mechanical ventilation modulates TLR4 and
IRAK-3 in a non-infectious, ventilator-induced lung injury model. Respir
Res 2010, 11:27.
12. Woodfin A, Voisin MB, Nourshargh S: PECAM-1: a multi-functional
molecule in inflammation and vascular biology. Arterioscler Thromb Vasc
Biol 2007, 27:2514–2523.
13. Ilan N, Mohsenin A, Cheung L, Madri JA: PECAM-1 shedding during
apoptosis generates a membrane-anchored truncated molecule with
unique signaling characteristics. FASEB J 2001, 15:362–372.
14. Fornasa G, Groyer E, Clement M, Dimitrov J, Compain C, Gaston AT,
Varthaman A, Khallou-Laschet J, Newman DK, Graff-Dubois S, Nicoletti A,
Caligiuri G: TCR stimulation drives cleavage and shedding of the ITIM
receptor CD31. J Immunol 2010, 184:5485–5492.
15. Villar J, Cabrera NE, Casula M, Valladares F, Flores C, López-Aguilar J, Blanch
L, Zhang H, Kacmarek RM, Slutsky AS: WNT/β-catenin signalling is
modulated by mechanical ventilation in an experimental model of acute
lung injury. Intensive Care Med 2011, 37:1201–1209.
16. Parker JC, Hernandez LA, Peevy KJ: Mechanisms of ventilator-induced lung
injury. Crit Care Med 1993, 21:131–143.
17. Tremblay LN, Slutsky AS: Ventilator-induced lung injury: from the bench
to the bedside. Intensive Care Med 2006, 32:24–33.
18. Fu Z, Costello ML, Tsukimoto K, Prediletto R, Elliott AR, Mathieu-Costello O,
West JB: High lung volume increases stress failure in pulmonary
capillaries. J Appl Physiol 1992, 73:123–133.
19. Pujin J: Is the ventilator responsible for lung and systemic inflammation?
Intensive Care Med 2002, 28:817–819.
20. Webb HH, Tierney DF: Experimental pulmonary edema due to
intermittent positive pressure ventilation with high inflation pressures.
Protection by positive end-expiratory pressure. Am Rev Respir Dis 1974,
110:556–565.
21. Herrera MT, Toledo C, Valladares F, Muros M, Diaz-Flores L, Flores C, Villar J:
Positive end-expiratory pressure modulates local and systemic inflamma-
tory responses in a sepsis-induced lung injury model. Intensive Care Med
2003, 29:1345–1353.
22. Newman PJ: The biology of PECAM-1. J Clin Invest 1997, 100:S25–S29.
23. Newman PJ, Berndt MC, Gorski J, White GC, Lyman S, Paddock C, Muller
WA: PECAM-1 (CD31) cloning and relation to adhesion molecules of the
immunoglobulin gene superfamily. Science 1990, 247:1219–1222.
24. Privratsky JR, Paddock CM, Florey O, Newman DK, Muller WA, Newman PJ:
Relative contribution of PECAM1 adhesion and signaling to the
maintenance of vascular integrity. J Cell Sci 2011, 124:1477–1485.
25. Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, Davis S, Ruddle
NH, Engelhardt B, Madri JA: Altered vascular permeability and early onset
of experimental autoimmune encephalomyelitis in PECAM-1-deficient
mice. J Clin Invest 2002, 109:383–392.
26. Mahooti S, Graesser D, Patil S, Newman P, Duncan G, Mak T, Madri JA:
PECAM-1 (CD31) expression modulates bleeding time in vivo. Am J
Pathol 2000, 157:75–81.
27. Muller AM, Cronen C, Muller KM, Kirkpatrick CJ: Heterogeneous expression
of cell adhesion molecules by endothelial cells in ARDS. J Pathol 2002,
198:270–275.
28. Bhatia RK, Pallister I, Dent C, Jones SA, Topley N: Enhanced neutrophil
migratory activity following major blunt trauma. Injury 2005, 36:956–962.
29. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM:
Disrupted pulmonary vasculature and decreased vascular endothelial
growth factor, Flt-1, and TIE-2 in human infants dying with
bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001,
164:1971–1980.
30. Krauss T, Kuhn W, Lakoma C, Augustin HG: Circulating endothelial cell
adhesion molecules as diagnostic markers for the early identification of
pregnant women at risk for development of preeclampsia. Am J Obst
Gynecol 1997, 177:443–449.
31. Soriano AO, Jy W, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ,
Horstman LL, Kett DH, Schein RM, Ahn YS: Levels of endothelial and
platelet microparticles and their interactions with leukocytes negatively
correlate with organ dysfunction and predict mortality in severe sepsis.
Crit Care Med 2005, 33:2540–2546.
32. Densmore JC, Signorino PR, Ou J, Hatoum OA, Rowe JJ, Shi Y, Kaul S, Jones
DW, Sabina RE, Pritchard KA, Guice KS, Oldham KT: Endothelium-derived
microparticles induce endothelial dysfunction and acute lung injury.
Shock 2006, 26:464–471.
33. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, Grossman W,
De Marco T, Yeghiazarians Y: Circulating endothelial microparticle levels
predict hemodynamic severity of pulmonary hypertension. Am J Respir
Crit Care Med 2008, 177:1268–1275.
34. Sinning JM, Losch J, Walenta K, Böhm M, Nickenig G, Werner N: Circulating
CD31+/Annexin V+microparticles correlate with cardiovascular
outcomes. Eur Heart J 2011, 32:2034–2041.
35. Buras JA, Holzmann B, Sitkovsky M: Animal models of sepsis: setting the
stage. Nat Rev Drug Discov 2005, 4:854–865.
36. Goldberger A, Middleton KA, Oliver JA, Paddock C, Yan HC, DeLisser HM,
Albelda SM, Newman PJ: Biosynthesis and processing of the cell adhesion
molecule PECAM1 includes production of a soluble form. J Biol Chem
1994, 269:17183–17191.
37. Muller WA, Weigl SA, Deng X, Phillips DM: PECAM-1 is required for
transendothelial migration of leukocytes. J Exp Med 1993, 178:449–460.
38. Shehabi Y, Seppelt I: Pro/Con debate: is procalcitonin useful for guiding
antibiotic decision making in critically ill patients? Crit Care 2008, 12:211.
39. Chiumello D, Carlesso E, Cadringher P, Caironi P, Valenza F, Polli F, Tallarini
F, Cozzi P, Cressoni M, Colombo A, Marini JJ, Gattinoni L: Lung stress and
strain during mechanical ventilation for acute respiratory distress
syndrome. Am J Respir Crit Care Med 2008, 178:346–355.
40. Protti A, Cressoni M, Santini A, Langer T, Mietto C, Febres D, Chierichetti M,
Coppola S, Conte G, Gatti S, Leopardi O, Masson S, Lombardi L, Lazzerini M,
Rampoldi E, Cadringher P, Gattinoni L: Lung stress and strain during
Villar et al. Critical Care 2014, 18:R41 Page 8 of 9
http://ccforum.com/content/18/2/R41mechanical ventilation: any safe threshold? Am J Respir Crit Care Med
2011, 183:1354–1362.
41. Slutsky AS, Ranieri VM: Ventilator-induced lung injury. N Engl J Med 2013,
369:2126–2136.
42. Maas M, Stapleton M, Bergom C, Mattson DL, Newman DK, Newman PJ:
Endothelial cell PECAM-1 confers protection against endotoxic shock.
Am J Physiol Heart Circ Physiol 2005, 288:H159–H164.
43. Bhattacharya S, Sen N, Yiming MT, Patel R, Parthasarathi K, Quadri S, Issekutz
AC, Bhattacharya J: High tidal volume ventilation induces
proinflammatory signaling in rat lung endothelium. Am J Respir Cell Mol
Biol 2003, 28:218–224.
44. Tsukimoto K, Mathieu-Costello O, Prediletto R, Elliott AR, West JB:
Ultrastructural appearances of pulmonary capillaries at high transmural
pressures. J Appl Physiol 1991, 71:573–582.
45. López-Aguilar J, Piacentini E, Villagrá A, Murias G, Pascotto S, Saenz-Valiente
A, Fernández-Segoviano P, Hotchkiss JR, Blanch L: Contributions of vascular
flow and pulmonary capillary pressure to ventilator-induced lung injury.
Crit Care Med 2006, 34:1106–1112.
doi:10.1186/cc13754
Cite this article as: Villar et al.: Soluble platelet-endothelial cell adhesion
molecule-1, a biomarker of ventilator-induced lung injury. Critical Care
2014 18:R41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Villar et al. Critical Care 2014, 18:R41 Page 9 of 9
http://ccforum.com/content/18/2/R41